Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Consumers

Tenative approval of lamivudine, nevirapine, and zidovudine fixed dose combination / PEPFAR

On February 8, 2012, the Food and Drug Administration granted tentative approval for a fixed dose combination tablet containing lamivudine, nevirapine, and zidovudine, 150 mg/200 mg/300 mg, indicated for use alone or in combination with other antiretrovirals for the treatment of HIV-1 infection.

"Tentative approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for purchase outside the United States under the PEPFAR program.

The product is manufactured by Macleods Pharmaceuticals Limited of Mumbai, India, and was reviewed under the FDA guidance titled Fixed Dose Combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously approved Antiretrovirals for the Treatment of HIV, developed to clarify the regulatory requirements that apply to such applications, possible issues of concern, and how they should be addressed. The guidance is intended to encourage sponsors to submit applications for combination and co-packaged products, and to facilitate submission of such applications to FDA..

You can find a complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan on the FDA web site.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

Page Last Updated: 08/21/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.